10x Genomics Inc. stocks have been trading up by 13.62 percent amid upbeat sentiment on its expanding single-cell sequencing market potential.
What Traders Need To Know
- Q2 2026 revenue came in at $151M, topping roughly $146.6M–$146.7M estimates, while the $0.14 loss per share beat the expected $0.24 loss.
- Management nudged 2026 revenue guidance up to $610M–$630M, slightly above prior guidance and Street expectations near $613.7M.
- Recent strength is tied to early demand for the Atera platform, a 74% gross margin, and modest core product growth despite headline revenue declining year over year on reported numbers.
- Stifel doubled its price target to $50 with a Buy rating, while Citi and Morgan Stanley also raised targets to $50 and $40 but stayed Neutral/Equal Weight.
- A new multi‑year collaboration with Lausanne University Hospital (CHUV) will deploy Flex Apex, Xenium, and Atera in advanced cancer diagnostics research.
Weekly Update Aug 03 – Aug 07, 2026: On Sunday, August 09, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 13.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
10x Genomics sits in a leading, premium niche of single‑cell and spatial omics, but remains an early‑stage profitability story. Revenue of ~$643M with 6–14% multi‑year CAGRs and a 69–70% gross margin confirms strong unit economics, yet EBIT and net margins remain slightly negative and ROIC is deeply negative. Balance sheet strength is a clear positive: minimal leverage (debt/equity ~0.1), current ratio ~5.9, >$500M cash, and positive free cash flow, supporting continued heavy R&D and commercialization.
Technically, TXG has flipped into a short‑term uptrend following the earnings‑driven gap from ~$43 to above $51, with the 52.25 intraday high now the near‑term pivot. The weekly range shows violent rotation but clear demand absorption of the 42.7 low and strong close near the top of the range, indicating institutional buying. On 5‑minute candles, post‑gap consolidation with elevated volume confirms support around $47–48. Actionable level: buy pullbacks toward $48 with a stop below $45, targeting a retest and breakout above $52.50.
More Breaking News
- WKHS Stock Draws Traders As EV Orders Grow And AI Pivot Emerges
- No Analysis Provided
- RKT Stock Dips After Big Q3 Earnings Beat
- MPT Stock Slides As Traders Weigh Debt, Dividend Risk
Fundamentally and strategically, TXG remains one of the highest‑quality assets in life‑science tools, structurally leveraged to a multiomics market growing >12% annually. The Atera launch, CHUV collaboration, and Proteintech Genomics integration, coupled with raised 2026 guidance to $610–630M and repeated Street target increases, support sustained outperformance versus broader Healthcare and Life Sciences tools peers. I see a clear path to scale‑driven operating leverage; fair value is $55–60 over 12–18 months, with support at $47 and first resistance at $52–53.
Quick Financial Overview
10x Genomics Inc. put up Q2 2026 revenue of $151M, a clean beat versus the ~$146.6M–$146.7M range the Street expected. Earnings were still negative at a $0.14 loss per share, but that was better than the projected $0.24 loss. Under the hood, gross margin improved to 74%, helped by core product strength and mix, even though reported revenue fell year over year due to one‑off patent settlement revenue in the prior period.
From a growth lens, TXG’s trailing revenue sits around $643M with high‑single‑digit growth on a like‑for‑like basis and a solid 6.0% three‑year revenue CAGR. Guidance for 2026 now stands at $610M–$630M, a modest raise and slightly above consensus near $613.7M, signaling cautious confidence. The balance sheet is liquid, with a current ratio of 5.9, minimal leverage (total debt to equity around 0.1), and over $500M in cash, giving the company room to keep funding R&D and platform launches like Atera without near‑term financing pressure.
The weekly chart shows TXG ripping from the mid‑$40s to above $52 this week, before settling near $51.81, a sharp move that likely reflects the earnings beat and price‑target hikes. Intraday, a single wide 5‑minute bar from roughly $45.51 to $52.22 with a close near $52.03 points to a high‑volatility squeeze, likely on news flow and upgrades. Valuation is rich with a price‑to‑sales above 10 and negative returns on equity and assets, so traders are paying for growth, technology leadership, and the expanding multiomics backdrop rather than current profits.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.